Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.
Mayne Pharma has announced the upcoming retirement of non-executive director Dr Kathryn MacFarlane from its board at the end of May 2026, following her appointment as chief executive of a US-based biopharma company. Dr MacFarlane, who joined the board in 2022 and chairs the Science, Technology and Medical Committee, is being thanked by the board for her service.
In response to her departure, Mayne Pharma has begun a formal process to recruit an additional non-executive director with suitable skills and experience. The board has engaged an independent executive recruitment firm to oversee the search, signalling a focus on maintaining strong governance and scientific oversight as the company continues to pursue its specialty pharma growth strategy.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is an ASX-listed specialty pharmaceutical company that commercialises novel medicines aimed at providing safer and more accessible treatments. The company is a leader in dermatology and women’s health in the United States and also offers contract development and manufacturing services globally, underpinned by a 40-year track record in innovative oral drug delivery systems.
Average Trading Volume: 520,407
Technical Sentiment Signal: Sell
Current Market Cap: A$184.4M
Learn more about MYX stock on TipRanks’ Stock Analysis page.